Our resource hub to discover reports, policy papers and other forms of informative content
Ontario PreBudget Submission
Ensuring timely access and availability of innovative medicines and vaccines is a critical component. Not only will this support important provincial patient needs, it will also create an environment which is more open to future healthcare research and investment.
Increasing Access to Innovative Medicines
The impact of the COVID-19 pandemic has shifted the health landscape in Canada. While the federal government has demonstrated its ability to react to an unprecedented health crisis, doing so has also sharpened the focus on domestic capacity and innovation in the life sciences sector.
Throughout the pandemic, we could not be prouder of our members’ collaborative efforts worldwide. From the onset, they worked toward agreements with nations and competitors to increase manufacturing capacity and minimize pharmaceutical supply chain disruption. IMC members demonstrated the industry’s value to the world, as the critical importance of reliable access to medicines was brought into focus.
Alberta Budget Submission 2023
Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The association advocates for policies that promote the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. In addition, it supports the commitment of its members as valued partners in the Canadian healthcare system.
The association represents 50 companies, which invest nearly $1.4 billion annually in research and development. In this way, it nurtures a high value-added knowledge economy while contributing $8 billion to the national economy.
The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
Addendum to IMC Submission on Drugs for Rare Diseases
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.